Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1

Interventions

Gemcitabine 31 Cisplatin 22 pembrolizumab 21 Magnetic Resonance Spectroscopy 18 Specimen Handling 16 durvalumab 11 Mitomycin 10 enfortumab vedotin 9 avelumab 9 Cystoscopy 9 Nivolumab 8 Fluorouracil 8 Carboplatin 8 Radiation 7 Cystectomy 7 atezolizumab 5 Transurethral Resection of Bladder 5 Radiotherapy 5 Mitozytrex 5 Immunoglobulin G 5 Docetaxel 5 Disulfides 5 Biopsy 5 tremelimumab 4 sacituzumab govitecan 4 erdafitinib 4 dehydroftorafur 4 Platinum 4 1,2-diaminocyclohexaneplatinum II citrate 4 disitamab vedotin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Dutasteride × 90 days × Clear all

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡